Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the six months ended 30 June 2022 on Tuesday 20 September 2022.

A meeting for analysts will be held at 9.30am on the day of the results at Investec Bank plc, 30 Gresham Street, London EC2V 7QP. To register for the meeting, analysts should contact Buchanan at alliancepharma@buchanan.uk.com.

A live webcast of the analyst meeting will be accessible via the following link: https://webcasting.buchanan.uk.com/broadcast/6307905bda906b287e99fad3

A recording of the webcast will be made available following the meeting at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors.

For further information:

Alliance Pharma plc
Head of Investor Relations: Cora McCallum
+ 44 (0)1249 466966
ir@allianceph.com

Buchanan
Mark Court / Hannah Ratcliff
+ 44 (0)20 7466 5000
alliancepharma@buchanan.uk.com

Numis Securities Limited
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
+ 44 (0)20 7260 1000

Investec Bank plc
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
+ 44 (0) 20 7597 5970

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com